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Abstract 
In recent years, ciprofloxacin resistant (CpR) Aeromonas veronii and A. hydrophila 
strains have been isolated from the wounds of patients receiving leech therapy. Genome 
comparisons of these CpR isolates revealed the presence of chromosomal mutations in gyrA and 
parC as well as the gain of qnrS2 on either a large, 34 kb, conjugatable, low-copy plasmid, 
pAv42, or on a small, 6.8 kb, high-copy plasmid, pAh1471. The minimum inhibitory 
concentration, MIC, for Cp of these clinical isolates ranged from 1 to ≥32 µg/mL and some 
harbored a qnrS2 containing plasmid. We wanted to assess the contributions of these factors in 
an isogenic background. To this end, gyrA S83I and parC E91K mutations were introduced 
individually and in combination into a Cp-sensitive leech isolate, A. veronii Hm21. The pAh1471 
was modified to encode a kanamycin resistance cassette. The resulting plasmid, pEL1, was 
electroporated into these four genetic backgrounds. pAv42 was conjugated into the four recipient 
strains by selecting for elevated Cp resistance. The genomes of all 12 strains were sequenced to 
screen for any secondary mutations, and Cp resistance was evaluated by E-tests. The results 
showed that the wild-type, gyrA, parC, and gyrA/parC mutants had a Cp MIC of 0.003, 0.094, 
0.003, and 0.25 µg/mL, respectively. Furthermore, the presence of pEL1 or pAv42 increased the 
resistance by 0.032-3.0 µg/mL. These indicates that the presence of qnrS2 had synergistic effect 
on the MIC and that copy number did not affect MIC. In addition, no strain was CpR, which was 
observed in a number of the clinical isolates, suggesting that additional mutations contribute to 
Cp resistance. Ten lineages of Hm21RS gyrA parC pAv42 were grown under Cp selective 
pressure. Those grown in 2.0 μg/mL Cp acquired additional mutations and increased MICs. Key 
mutations discovered after sequencing populations include pncB T77P and phoE Δ367. Future 
investigations will clone these mutations into Hm21RS to assess their impact on Cp resistance.  
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Introduction 
Since their discovery, antibiotics have revolutionized healthcare for their capability to 
eliminate pathogenic bacteria from human hosts. This has proven useful in treating diseases 
caused by lethal pathogens. They have contributed to a global increase in life expectancy over 
the past century (Odonkor & Addo, 2011). However, microbes have rapidly developed novel 
mechanisms to survive these agents. This has led to roadblocks in treatment and portends a 
“post-antibiotic world,” where currently treatable infections may once again prove fatal 
(Andersson & Hughes, 2010).  
Preventing, or at least delaying this from occurring is a vital step to avoiding a pandemic 
caused by poly-drug resistant strains (Odonkor & Addo, 2011). Research exploring causative 
factors, and bacterial genetic determinants has contributed to a wide repository of information on 
this subject. These studies aid in the discovery of resistance mechanisms and novel drug targets 
for antibiotic therapy.   
Resistance traits have developed through mutations and horizontal gene transfer, with the 
latter facilitating rapid increases in resistance among bacterial populations (Andersson & 
Hughes, 2010). The overuse of antibiotics in anthropogenic environments such as hospitals has 
led to the buildup of these compounds and has facilitated selection for resistant strains (Dancer et 
al., 2006; Rizzo et al., 2013). There is evidence of higher concentrations of antibiotic resistance 
genes from sources like wastewater treatment plants and agricultural sites (Gupta, Shin, Han, 
Hur, & Unno, 2018; Suzuki, Pruden, Virta, & Zhang, 2017). These studies show that human use 
of antibiotics has increased the prevalence of antibiotic resistant bacteria. This is especially 
concerning in clinical settings, where patients can be susceptible to these infections.  
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Hirudotherapy, the therapeutic use of medicinal leeches in clinical settings, has been 
applied with increasing frequency. Specifically, the anticoagulants and anti-inflammatory 
substances secreted by Hirudo verbana have been shown to help improve recovery from venous 
congestion after transplantation and replantation surgeries (Jha et al., 2015). In addition, leeches 
aid in the removal of pooled blood from venous congestion, so that fresh blood can be cycled in 
(Whitaker, Rao, Izadi, & Butler, 2004). Venous congestion is a significant obstacle to recovery 
following reconstructive surgery. One study showed that the addition of hirudotherapy improved 
salvage rates by 77.9% (n=227) (Whitaker, et al., 2012). However, there have been reports of an 
increased incidence of ciprofloxacin (Cp) resistant (CpR) Aeromonas spp. infections in patients 
who have received hirudotherapy (Redgrave, Sutton, Webber, & Piddock, 2014; Whitaker et al., 
2011). These Aeromonas infections often occur during the attachment of a leech to the open 
wounds of patients. These infections range from minor complications such as cellulitis to major 
Aeromonas septicemia infections (Bauters et al., 2007). Fluoroquinolones (FQs) such as Cp or 
levofloxacin are the typical treatment for Aeromonas infections. (Whitaker et al., 2011) FQs are 
a class of antibiotics that target the DNA replication proteins DNA gyrase and topoisomerase IV. 
These proteins are involved in the coiling and uncoiling of DNA during the replication process. 
Specifically, the DNA gyrase uncoils DNA by introducing double stranded breaks to reduce 
tension. The enzyme is composed of two subunits, coded by gyrA and gyrB (Reece & Maxwell, 
1991; Roca, 1995). In an ATP dependent reaction, it is also involved in supercoiling DNA 
(Drlica & Zhao, 1997). The topoisomerase IV cuts the replicated strands of DNA after 
replication is complete so they are do not overlap. It is structurally similar to DNA gyrase and is 
coded for by parC and parE (Drlica & Zhao, 1997; J. Kato et al., 1992; Jun-ichi Kato et al., 
1990). 
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 FQs block this process by first passing though the outer membrane via porins using 
passive diffusion and pass through the cytoplasmic membrane though diffusion (Hooper, 1999). 
After entering the cell, FQs link to their target proteins and inhibit them. FQs halt DNA gyrase in 
the middle of the reaction, and cleaved DNA does not rejoin (Drlica & Zhao, 1997; Cullis et al., 
1997). Similarly, Topoisomerase IV is unable to rejoin DNA after cleavage after FQ 
interference. This prevents DNA replication, and eventually leads to cell death in both gram-
negative and gram-positive bacteria (Drlica & Zhao, 1997). DNA gyrase is the primary target in 
gram-negative bacteria, while topoisomerase IV is the primary target in gram-positive (Drlica & 
Zhao, 1997; Hooper, 2001). Ciprofloxacin (Cp) is the fluoroquinolone typically used in human 
administration. Enrofloxacin was used therapeutically and prophylactically in livestock. The use 
of enrofloxacin has led to CpR strains (Nelson et al., 2007; Smith et al., 1999). 
Patients receiving hirudotherapy are routinely treated with ciprofloxacin prophylactically. 
With the increased incidence of CpR strains among Aeromonas spp., prophylaxis with 
ciprofloxacin has become increasingly ineffective. Therefore, breakthrough infections have 
occurred despite prophylaxis (Iovine & Blaser, 2004). An investigation has been made to 
identify the source of these resistant strains. 
Aeromonas spp. are gram-negative, rod-shaped, and motile facultative anaerobes 
belonging to the family Aeromonadace in the phylum of Gammaproteobacteria. A. veronii and 
A. hydrophila are known symbionts to leeches, residing in the crop (gut) of the animal. They aid
in the breakdown of blood meal in the leech via β-hemolysis using a Type II secretion system 
(TIISS) (Maltz & Graf, 2011). These same colonization factors cause pathogenicity in human 
and other hosts (Maltz & Graf, 2011). After inactivating the TIISS in A. veronii via transposon 
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mutagenesis, the strain was unable to colonize the leech, indicating that this system is also 
critical for symbiosis (Maltz & Graf, 2011).  
There are several genetic determinants for Cp resistance: mutations in the genes coding 
for DNA gyrase and topoisomerase IV, gyrA and parC respectively. There are also plasmid 
mediated resistance genes that increase MIC. One class are efflux pumps, which actively 
transport compounds out the cell; these include qepA, oqxAB, and qacBIII (Rodríguez-Martínez, 
et al., 2016). There is also an enzyme coded by the gene aac(6’)-lb-cr that acetylates quinolone 
compounds to weaken their potency. The third class of plasmid mediated resistance proteins are 
those in the Qnr family. These proteins are typically understood to protect targets from inhibition 
by binding to the fluroquinolone. qnrS2 has been found in Aeromonas spp. on IncU-type 
plasmids, as a part of a mobile insertion cassette (Cattoir et al., n.d.; Rodríguez-Martínez, et al., 
2016). 
Mutations in gyrA and parC occur in the quinolone resistance determining region 
(QRDR) (Rodríguez-Martínez, et al., 2016) and can be characterized as S83I for gyrA and E91K 
for parC, as they are in this study. A review of Escherichia coli, Mycobacterium tuberculosis, 
Staphylococcus aureus and Shigella dysenteriae revealed that most of the mutations leading to a 
reduced sensitivity to Cp are located in similar region on gyrA and parC but the exact amino acid 
altered depends on the species and the magnitude of the change (Drlica & Zhao, 1997). 
Previously, we found that both gyrA and parC mutations have been found in many Aeromonas 
spp. isolates from sources ranging from medicinal leeches to clinical samples.  
Previous studies have analyzed the environmental determinants that maintain resistant 
genotypes within Aeromonas populations. Trace amounts of Cp were detected within medicinal 
leech crop tissue sourced from Leeches USA ®, the only medicinal leech supplier approved by 
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the FDA (Beka, et al., 2018). This is most likely traced to the poultry blood used for feeding the 
leeches. The poultry are typically administered enrofloxacin, an analog of Cp, as part of their diet 
(Morales-Gutiérrez et al., 2015; Vieira et al., 2011). Enrofloxacin is processed into Cp within the 
livers of livestock such as poultry and then enters their bloodstream. The Cp containing blood is 
ultimately fed to the leeches. These low levels of Cp have been shown to impose sufficient 
selective pressure for the development of CpR (Sartor et al., 2013). 
In a previous study, we sequenced the genomes of Aeromonas strains collected from 
clinical and leech samples and tested them for Cp resistance. Downstream analysis identified 
presence of mutations in gyrA and parC, as well as the presence of plasmid mediated resistance 
factor, qnrs2. In all but one CpR isolates an IncU type plasmid, e.g. pAv42, was detected. These 
IncU type plasmids carrying qnrs2 have been detected in other Aeromonas spp. strains. In 
virtually all cases, this gene is flanked by a mobile insertion cassette. In one strain, a small IncQ 
type plasmid, p1471, was detected that carried an identical qnrs2 gene (Beka, et al., 2018). 
Surprisingly, the Cp MIC of isolates containing the gyrA and parC mutations and qnrS2 ranged 
from 2 to >32 μg/mL, which is the upper limit of tests used. These data raise the question of the 
contribution of each mutation or gene to the gain of Cp resistance in Aeromonas veronii (Beka, 
et al., 2018). 
In this study, we characterized the contributions of mutations within gyrA and parC, 
along with plasmid mediated qnrS2 on the MIC of the A. veronii strain Hm21RS. Mutations and 
plasmids were introduced in a stepwise manner to assess their effect on MIC. Hm21 is a fully 
genotyped, well characterized and studied strain of A. veronii that has been used as a model 
system for its species. The current Hm21 strain used also harbors streptomycin and rifampicin 
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resistance for purposes of selection. We also grew Hm21RS gyrA parC pAv42 in Cp 
supplemented media to select for additional resistance traits.  
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Methods 
Creation of SNV Mutations Within Quinolone Resistance Determining Regions (QRDR) of 
Hm21RS 
Two chromosomal single nucleotide variant mutants of DNA replication genes gyrA (S83I) 
and parC (E91K) were constructed by allelic exchange and homologous recombination using the 
plasmid pKAS46, with selection marker for kanamycin resistance (KmR) and counterselection 
marker rpsL. PCR fragments were amplified using primers to incorporate the desired point 
mutations and included overhangs for fragments to anneal to cut restriction sites on the target 
vector via Gibson assembly. Primers were designed in lab by Meredith Mistretta M.S. and Dr. 
Jeremiah Marden.  
Plasmid Identification  
Plasmids were identified during the assembly process of a previous study by using NCBI 
Blast (Altschul et al., 1990). Sequencing reads were generated using an Illumina MiSeq with a 2 
x 250 protocol (Illumina, Inc., San Diego, CA). Reads were assembled de novo with scaffolding 
using CLC Genomics Workbench (CLC Bio-Qiagen, Aarhus, Denmark). Contigs were submitted 
to NCBI Blast to screen for matching plasmid sequences (Beka et al., 2018). 
Media and Growth Conditions 
All standard culturing steps were carried out in Lysogeny Broth (LB) (10 g/L Bacto 
Tryptone, 5 g/L yeast extract, 10 g/L NaCL). All solid media was prepared by adding 15 g/L of 
Bacto Agar (BD, Franklin Lakes, New Jersey) unless otherwise stated. Any rifamycin (Rif) was 
supplemented in media at 20 μg/mL and any streptomycin (Strep) or kanamycin (Km) was 
supplemented at 100 μg/mL. SOB media used for preparation of electrocompetent cells was 
prepared with 20 g/L Bacto-tryptone, 5g/L yeast extract, 0.5g/L NaCl, 10 mL/L 250mM KCl 
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before autoclaving. Remove liquid added after autoclaving from this volume (e.g. if 2 L of media 
are being made, then make a solution of 1980 L). After autoclaving, the 10 mL/L 1M MgSO4 is 
added to reach the final target volume. For E-Testing, Cation Adjusted Muller Hinton II Media 
was used (BD), and supplemented with 15 g/L of Bacto Agar.  
Preparation of Electrocompetent Cells 
A. veronii electrocompetent cells were prepared by growing the bacteria on solid media 
with the appropriate antibiotics overnight at 30°C and transferring an isolated colony to an 
overnight liquid culture with antibiotics. 2.5 mL of overnight culture was transferred to 250 mL 
of sterile SOB media (20g/L Bacto-tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 10 mL/L 250mM 
KCl, 10 mL/L 1M MgSO4) and subcultured at 30°C to an OD600 of 0.5-0.6A. Electrocompetent 
cells were washed through a series of centrifugation steps. The 250 mL subculture was 
transferred to a 500 mL centrifuge tube and spun down at 10,000xg for 10 minutes at 4°C. 
Supernatant was removed and pellet was resuspended in 25 mL of chilled salt free solution; 
either autoclaved nanopure water, or 10% glycerol if they are to be placed in frozen storage. 
Suspension was transferred to chilled 50 mL conical tubes and spun down at 10,000xg for 10 
minutes at 4°C. Supernatant was removed and pellet was resuspended in 1.5 mL of salt free 
solution. Suspension was transferred to a 2 mL microcentrifuge tube and spun down at max 
speed for 10 minutes at 4°C. The cells were resuspended in 750 μl of water or 10% glycerol and 
separated into 100 μl aliquots used for electroporation. For storage, aliquots were flash frozen in 
liquid nitrogen and kept at -80°C. 
Construction of pEL1 
A small (6.8kb) high copy plasmid, p1471, was isolated from an A. hydrophilia strain, 
JG1471, cultured from the intraluminal fluid (ILF) of a farmed leech, sourced from Leeches 
11
USA. The Km resistance cassette and the E. coli MCS from pKAS46 were cloned into p1471 
through a Gibson assembly reaction (LaMarre & Graf, 2016). Completed vectors were 
electroporated into E. coli DH5α-λpir and validated through sanger sequencing. The selected 
vector was purified using a Qiagen plasmid purification kit. Both the QIAprep® Spin Miniprep 
Kit, and the CompactPrep® Plasmid Maxi Kit (Qiagen N.V., Hilden, Germany) were effective 
for extraction. Plasmid DNA concentration was quantified using a Qubit 4 Fluorometer (Thermo 
Fischer Scientific, Waltham, Massachusetts). Sample purity was quantified using a Nanodrop 
One Spectrophotometer (Thermo Fischer Scientific). 
Introduction of pEL1 
pEL1 plasmid DNA was electroporated into freshly made electrocompetent A. veronii under 
the following conditions: 1.8V in a 0.2cm cuvette. SOC (SOB + 20 mL/L of 20% glucose) 
recovery medium was prewarmed to 30°C, and any materials used pre-electroporation were 
chilled to keep cell samples cold. Cell/vector mixtures were left to set for 10 minutes before the 
reaction was run, and typically 50ng of vector was used for the transformation. After a one-hour 
recovery at 30°C, tubes were serially diluted in a 10:1 ratio twice and spread plated on selection 
media. The original tube was centrifuged, the pellet was resuspended in 40ul, and the entire 
volume was plated.  
Construction of Hm21RS pAv42 and Hm21RS Mutant pAv42 Strains 
Hm21RS pAv42 strains were created by following a standard mating protocol (Graf et 
al., 1994). Cells were grown on solid media with antibiotics, then in overnight culture with 
antibiotics before being subcultured to an OD600 of ~0.3A. Cells were mixed in a 1:1 ratio based 
on the following CFU/mL calculation: � 1
𝑂𝑂𝐷𝐷600∗3∗108� ∗ 2 ∗ 108 = 𝑥𝑥 𝑚𝑚𝑚𝑚. Non-mating controls were 
also made. Cell mixtures were centrifuged at 8000 x g for 2 min at 4°C and plated on LB agar for 
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16 hours. The spot was scraped up with a sterile inoculating loop and resuspended in 1 mL of 
PBS. The cell mixture was serially diluted in a 1:10 ratio four times, and the initial mixture, 
second, and fourth dilutions were plated using a spiral plater in E50 mode. Selection plates were 
incubated for 16-18 hours. 
Because pAv42 only codes for Cp resistance, and does not carry an alternate selection 
marker, transconjugants were selected for by plating suspension on Rif 20 μg/mL and Strep 100 
μg/mL media with varying concentrations of ciprofloxacin. Concentrations used for each 
conjugation were influenced by the MIC of the corresponding pEL1 strain. A successful 
transformation and appropriate selective antibiotic concentration were indicated by little to no 
growth on the Hm21RS control plates, while the experimental plates had significant colony 
counts. Colonies were restreaked on solid media, and the transformation was validated via 
colony PCR with pAv42 specific primers.  
A small range of Cp concentrations were used, typically in increments of 0.1 μg/mL, with 
smaller changes in concentration in media until an appropriate concentration was determined. 
Cipro concentrations used to select for each transformation were 0.8 μg/mL for Hm21RS gyrA 
S83I parC E91K, 0.05 μg/mL for Hm21RS parC E91K, 0.10 μg/mL for Hm21RS gyrA S83I, 
and 0.025 μg/mL for Hm21RS.  
PCR Confirmation of Conjugation 
Primers specific to pAv42 were used to confirm conjugates with a GoTaq Green Master 
Mix (Promega, Madison, Wisconsin) for the PCR reaction. Av42 was used as a positive control 
while Hm21RS was used as a negative control. pEL1 transformants were confirmed using 
primers specific to qnrs2 but were originally designed for pAv42. Expected product from both 
primer sets was about 500 bp.  
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Determining the MIC  
In accordance with the e-test guidelines specified by BioMeriux, isolates were grown on 
solid LB media overnight for 16-18 hours at 30°C with appropriate antibiotics. Isolated colonies 
were resuspended in 0.85% NaCl to match a 0.5 McFarland turbidity standard. Cation adjusted 
Muller Hinton II (CAMHII) agar was prepared by using CAMHII Media mixed with 1.5% Bacto 
Agar. Each plate had roughly 25 mL of media added to mitigate variance in diffusion. 
Ciprofloxacin E-test strips (BioMeriux, Marcy-l'Étoile, France) with an analytical range of 0.002 
to ≥32 μg/mL were applied to plates and incubated at 30°C for 16-18 hours (Bonaventura et al., 
1998). MICs were determined using the interpretation criteria on the BioMeriux website.  
Determining Growth Rates  
Strains were grown in a 96 well plate in triplicate in either LB Rif 20 Strep 100 or LB Rif 20 
Strep 100 Cp 0.01. Wells on the edges of the plate were left empty and used as blanks. 
Measurements were taken on a Biotek Synergy HTX plate reader (BioTek, Winooski, Vermont) 
every 15 minutes for 18 hours at OD600.  
Extraction of Genomic DNA  
Total DNA was extracted to prepare samples for downstream analysis of genome content. 
Part nine of the DNA extraction protocol from Lucigen Masterpure Complete DNA & RNA 
extraction kit was followed (LGC, Teddington, UK) (Miller et al., 1988). DNA concentration 
and quality was measured using a Nanodrop One Spectrophotometer and Qubit 4 Fluorometer.  
Preparation of Genome Libraries and Sequencing 
DNA samples were prepared for sequencing initially by using either Illumina Nextera XT or 
Nextera Flex. Nextra XT protocol was followed as written. Nextera Flex protocol was followed 
by using input DNA of 100-500ng, and library construction was validated using a Qubit 4 
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Fluorometer and Agilent tape station with D5000 HS screen tapes (Agilent, Santa Clara, 
California). Libraries were diluted to 4 nM and pooled no more than a week before sequencing 
Libraries were sequenced on a 2 x 250 bp protocol on an Illumina MiSeq.  
Sequence Analysis 
Reads were quality filtered and trimmed using Trimmomatic 0.36. Reads were trimmed to 
remove Nextera paired end adapter sequences, and quality filtered with a sliding window of 4:20, 
leading and trailing cutoff scores of 20, and any reads under 70 bp were removed. Trimmed 
reads were mapped to the complete Hm21 assembly using Breseq 0.27.2 and later 0.35.0, with 
expected plasmids added to the reference sequence when necessary (Deatherage & Barrick, 
2014). To identify percent fixation for alleles -p flag was called to run the program in population 
mode. This flag was not used when analyzing the transformants/transconjugants. Result tables 
were transferred to Microsoft Excel and compiled to identify common mutations between 
isolates/lineages (Microsoft, Redmond, Washington).  
Evolution of Hm21RS gyrA S83I parC E91K pAv42 in Presence of Ciprofloxacin 
Hm21RS gyrA parC pAv42 was grown overnight in Rif 20 Strep 100 LB from solid 
media, and subcultured in Rif 20 Strep 100 LB until it reached OD600 of 0.6A. 10 μl of culture 
was added to 590 μl of previously prepared antibiotic stock in row 1 of a 96 deep well plate 
(Greiner Bio-One, Kremsmünster, Germany). Two plates were used, where rows A-F had either 
LB Rif 20 Strep 100 Cp 0.01, or LB Rif 20 Strep 100 Cp 2.0, and in both plates rows G and H 
had LB Rif 20 Strep 100 as controls. Samples were incubated at 30°C for 24 hours. The next 
column had fresh LB with appropriate antibiotics added and 10 μl of the previous day’s culture. 
300 μl of incubated culture was pelleted and frozen at -20°C for genomic DNA extraction at a 
later date, and 200 μl was mixed with glycerol for storage at -80°C. Incubation/refresh cycle was 
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repeated for 7 days, and DNA from 7th day lineages was sequenced and analyzed. This process is 
visualized in Figure 1. 
Evolution Mutant Analysis  
Mutant tables were transferred from breseq output to a Microsoft Excel workbook for 
analysis. A boolean array formula was used to identify mutations that were also found in the LB 
controls. The array indexed the sequence ID, position (±50bp), and gene name, space and 
nonbreak space characters were removed during calculations using the substitute function. Power 
query was called to compile all tables and remove any rows that matched the “in LB” criteria. 
Any mutations that were below 10% in the population were removed. The master hitlist used an 
index, match formula to assess a reference table for a matching row by using an array that 
queried the evidence, seq id, and position columns. 
Data Analysis  
Data were analyzed using Graphpad Prism 6 (Graphpad Software, San Diego, 
California). A Kruskal-Wallis ANOVA analysis was run to test statistical significance of the 
MIC data, and a Kruskal-Wallis multiple comparisons test was used to observe statistical 
significance between these samples. Doubling time for growth curves was also calculated using 
this program, using a logistic growth analysis. Y0 and YM for this analysis were constrained to 
be >0.  
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Results 
Introduction of Plasmid into Hm21RS Strains 
For the introduction of pAv42, successful selection was indicated by little to no growth 
on the Hm21 negative control plates, with isolated colonies found on experimental selection 
plates at lowest dilution. Confluent growth was never observed on any plates. Electroporation of 
pEL1 into Hm21RS strains had varying success. The plasmid had low rates of transformation 
when purified from E. coli. Transformation was more successful when the plasmid was purified 
from A. veronii. All isolates were confirmed via PCR with primers listed in Table 1. 
Validation of Mutations in Transconjugants 
The presence of the introduced mutations and plasmids was validated in the 
transconjugants using breseq. In addition, this allowed the detection of secondary mutations that 
arose within the transconjugants. There is the possibility that the Cp used for selection of 
transconjugants would introduce Cp resistance mutations in the genome, and falsely elevate Cp 
MIC. To mitigate this, all strains were sequenced and analyzed using Breseq; a software that 
displays mutations detected from a bowtie alignment in HTML format. This output reported any 
mutation that was ~100% of associated reads. The table generated from the analysis indicated 
minimal secondary mutations within chosen transconjugants. One strain, Hm21RS pEL1 still 
needs sequencing and analysis. However, Cp resistance mutations are not expected with 
electroporation.  
Copy Number Analysis  
We previously assumed that copy number of various qnrs2 containing plasmids would 
proportionately impact MIC. To assess this, we inferred copy number from breseq data, using 
percent coverage was used as an analog for copy number, coverage of chromosome was 
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compared to plasmid coverage. The copy number for pAv42 was lower than that of pEL1, with 
an average coverage ratio of 6.34 and 62.00, respectively. This was calculated using the 
following formula 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 % 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝐶𝐶
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐿𝐿𝐶𝐶𝐿𝐿𝐶𝐶𝐿𝐿ℎ
𝐶𝐶ℎ𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶 % 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝐶𝐶
𝐶𝐶ℎ𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶 𝐿𝐿𝐶𝐶𝐿𝐿𝐶𝐶𝐿𝐿ℎ . The interpretation is that copy number for pAv42 was 
lower than pEL1, similar to the high copy number of pEL1’s predecessor, p1471. This finding is 
in agreement with what was previously assumed (LaMarre & Graf, 2016). 
CpR level of Hm21RS Derivatives Carrying gyrA, parC, pEL1, and pAv42   
We wanted to assess the effect of CpR determining genetic factors on Cp MIC. To do this 
we performed E-Tests in triplicate for each strain. We found that there was no significant 
difference between isolates that have pEL1 or pAv42 (P > 0.999). In all cases, the addition of a 
plasmid containing qnrs2 elevates MIC. While a parC mutation on its own did not confer an 
increase in MIC, each double mutant presented a synergistic effect on MIC. A Kruskal-Wallis 
one-way ANOVA test showed a P value of 0.003. The multiple comparisons test found 
significant differences between Hm21RS gyrA parC pEL1 vs. Hm21RS parC, Hm21RS gyrA 
parC pAv42 vs. Hm21RS, and Hm21RS gyrA parC pAv42 vs. Hm21RS parC (P < 0.05).  
MIC Testing of Evolved Populations of Hm21RS gyrA parC pAv42 
To assess the development of increased resistance after prolonged selective pressure, we 
performed a preliminary MIC test using E-Tests (BioMeriux). For populations grown under 0.01 
μg/mL Cp conditions, the MIC remained within the range of 3-4 μg/mL. An MIC of 3 μg/mL 
was originally observed for Hm21RS gyrA parC pAv42. Populations grown in 2.0 μg/mL 
evolved MICs above 3.0μg/mL, ranging from 6 - >32 μg/mL. We found that a concentration of 
2.0 μg/mL was sufficient for developing CpR isolates within a population.  
 
 
18
Identification of Potential CpR Mutations 
Each population that had an elevated Cp MIC phenotype had mutations that confer Cp 
resistance. These were validated by sequencing DNA from seventh day populations and 
analyzed using Breseq. Mutations detected by the program were compared to the LB controls, 
and any mutations that were not present in these LB controls were considered candidate 
mutations. When matching the position for mutations found in experimental populations over 
control populations, the array also searched for any matching mutations 50 bp in either direction. 
Meaning that any mutation that matched the LB controls was filtered out if a similar mutation 
(querying for gene name, position, and contig) was found in a 100bp range. The final candidate 
table removed any genes that fell below 10% frequency within the population. These filtering 
steps were applied in Microsoft Excel and used to identify significant candidate mutations found 
within these populations. Additionally, there was a master hit-list that searched for exact 
matches of mutations across all populations and displayed the percent fixation for each 
population. pncB T77P occurred in two lineages (2C7, 2E7) with 100% frequency for both. 
pncB codes for nicotinate phosphoribosyltransferase, an enzyme responsible for the rate limiting 
step in the NAD salvage pathway, and is essential for cell growth (Shackelford et al., 2010). A 
single base frameshift deletion in phoE at position 367 occurred in lineage 2F7 at a frequency of 
53.2%. phoE codes for a pore protein and the mutation occured within the trimer interface and 
eyelet codes for a pore protein, and the mutation occurs within the trimer interface and eyelet 
domains (Marchler-Bauer, et al., 2017). 
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Growth Rates 
Growth rates are used to evaluate the kinetic properties of bacterial growth in liquid 
media, and to document any growth defects present in strains. The growth rates were tested for 
all strains in medium without antibiotics and with 0.01 µg/mL of Cp. All isolates had similar 
growth rates in LB and except for Hm21RS and Hm21RS parC in LB with 0.01 Cp µg/mL Cp. 
All other strains had similar growth rates even when exposed to low levels of Cp (Figure 4). 
Unfortunately, the wells for Hm21RS gyrA with 0.01Cp were not inoculated. However, it would 
be expected that it would have similar growth rates in 0.01 Cp, as it has a higher MIC than both 
Hm21RS and Hm21RS parC. 
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Discussion 
Antibiotic resistance has become a growing concern within the medical field. Efforts 
have been made to learn about and combat these resistance factors. These include mutations in 
gyrA and parC, and plasmid mediated factors such as qnrs2. These genes and mutations were 
characterized separately and in combination to explore their impact on level of resistance to Cp. 
Additionally, there are novel mutations and genes that confer antibiotic resistance that are not 
well documented. Discovering these new factors is important as it can aid in development of new 
antibiotics. In this study, we identified several potential genes of interest.  
One hurdle in this study was moving pAv42 to the Hm21RS isogenic background. After 
facing challenges with cloning a KmR selection marker into pAv42, we decided to rely on 
plasmid’s ability conjugate itself. We developed a mating protocol that selected transconjugants 
by exposing them to different concentrations of Cp after an overnight mating to Av42, the donor 
strain of pAv42. 
Initially it was thought that the T6SS in Hm21RS would kill Av42 before conjugation could 
complete, and preliminary data suggested that a 10:1 ratio of Hm21RS:Av42 would reduce the 
killing activity, however, a follow-up killing assay found better survival rates when cultures 
were mixed in a 1:1 ratio. Therefore all conjugations after the first month of experiments were 
completed in a 1:1 donor recipient ratio.  
 Hm21RS pAv42 transconjugants and Hm21RS pEL1 transformants were sequenced and 
screened for mutations with Breseq. Those with the least mutations were selected for further 
analysis. This step was necessary as the Cp used in the selection media had potential for causing 
unwanted Cp resistance mutations. However, additional mutations in transconjugants were 
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minimal, as indicated by Breseq results (Table 3). We also sequenced and screened the four non 
plasmid strains and mapped the acquisition of mutations for each strain in this study (Figure 2). 
 After confirming all isolates, we screened the Cp MIC values of these strains using E-
tests. The significant difference between Hm21RS and Hm21RS gyrA parC pAv42 shows that 
these factors in combination greatly effect resistance. On their own, each factor slightly impacted 
MIC. parC did not cause any elevation of Cp MIC on its own, but combination with gyrA 
administered a synergistic effect. This same phenomenon was observed in strains with pAv42 
and pEL1.  
Topoisomerase IV is the primary target of Cp in gram-positive bacteria, and as expected, 
the mutation on its own did not impact MIC in Hm21RS. However, the gyrA S83I mutation 
elevated MIC from 0.003 μg/mL to 0.125 μg/mL. When both mutations were present in the 
genome, parC established a synergistic effect on the MIC, raising it to 0.38 μg/mL.  
 Previously it was stated that p1471 and by association, pEL1 would have a higher copy 
number than pAv42 (Beka et al., 2018; LaMarre & Graf, 2016). In this study copy number was 
validated by comparing percent coverage of reads of plasmid and chromosome after 
resequencing using the following formula; 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 % 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝐶𝐶
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐿𝐿𝐶𝐶𝐿𝐿𝐶𝐶𝐿𝐿ℎ
𝐶𝐶ℎ𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶 % 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝐶𝐶
𝐶𝐶ℎ𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶 𝐿𝐿𝐶𝐶𝐿𝐿𝐶𝐶𝐿𝐿ℎ . These findings indicated that 
pEL1 has a higher copy number in Hm21RS than pAv42. This is in agreement with previous 
assumptions. Despite this, plasmid copy number did not influence MIC in either direction 
(Figure 3). Alternate methods such as qPCR of qnrs2 on strains containing either plasmid, and 
qPCR on pAv42 and pEL1 would aid in validating these findings.  
Strains of A. veronii with elevated resistance were able to grow in low levels of Cp at 
similar rates to cultures grown in LB. Typically, resistance factors like gyrA and parC mutations, 
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and qnrs2 can slow growth. In isolation, this does not seem to be the case; all isolates shared 
similar growth rates in the absence of Cp. All isolates have similar growth behavior in 0.01 Cp, 
with the exception of Hm21RS parC and Hm21RS, which were slow to grow in this media. This 
is likely related to the low MIC values of these two strains. Previous studies found low levels of 
Cp in leech crop aid in the selection of CpR strains of Aeromonas spp (Beka, et al., 2018). These 
findings indicate that upon development of resistance traits, Aeromonas spp. survive well in the 
presence of Cp.  
To observe which mutations could lead to higher Cp MIC, populations of Hm21RS gyrA 
parC pAv42 were evolved under two selective pressures, 0.01 μg/mL and 2.0 μg/mL Cp. 
Mutations that increased fitness under these conditions would increase Cp resistance, and 
become more prevalent in the population. After an initial Cp MIC screen using E-Tests 
(BioMeriux), populations exposed to 0.01Cp had little to no increase in MIC, with a mean of 3.5 
μg/mL, a max of 4 μg/mL, and a standard deviation of 0.5. Populations exposed to 2.0 Cp 
developed increases in MIC ranging from 6 - >32 μg/mL, with a mean of 13.3 μg/mL, a max of 
>32 μg/mL, and a standard deviation of 9.1. The increased concentration proved to be effective
at selecting for resistance traits. Strains with a Cp MIC of >4 μg/mL are considered resistant. 
These findings are significant as it indicates that A. veronii strains with both gyrA and parC 
mutations, and qnrs2 readily mutate additional resistance traits under selective pressure.  
Therefore, exposure to low concentrations may lead to the development of additional 
resistance mutations (Beka et al., 2018). It has yet to be seen if these resistance traits also cause 
major growth defects. Other studies have exhibited that under selective pressure of low-level 
antibiotics, small mutations in combination confer high levels of resistance in Salmonella 
enterica (Wistrand-Yuen et al., 2018).  
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 There were several mutations of interest that were found after sequencing the evolved 
populations. pncB T77P was fully fixed in two separate populations. This gene codes for 
nicotinate phosphoribosyltransferase, which is responsible for the rate limiting step of the NAD 
salvage pathway (Heuser et al., 2007; Shackelford et al., 2010). This is the only candidate 
mutation to reach 100%, and its occurrence in two separate lineages suggests that this mutation 
confers Cp resistance. The mutation is a threonine to proline amino acid change about 77 
residues before the active site of the protein primary structure. However, a proline residue 
change can indicate the end of an α-helix or β-sheet, altering secondary structure. Given that this 
protein is necessary for metabolism, and assuming that there are no paralogs, the protein would 
need to maintain proper function while also interacting with Cp. Additionally, Cp and nicotinate 
share some structural similarities, and an enzyme targeting nicotinate might also interact with Cp 
to reduce potency. 
 A frameshift deletion in phoE also occurred at a high rate in one lineage. This is a subunit 
of a pore protein, and the frameshift occurred within the trimer interface and eyelet domain and 
likely rendered the subunit nonfunctional (Marchler-Bauer, et al., 2017). Cp typically diffuses 
through cellular porins (Rodríguez-Martínez, Velasco, Pascual, Cano, & Martínez-Martínez, 
2011), and rendering one nonfunctional can reduce the amount of antibiotics entering the cell via 
passive diffusion. This mutation occurred in lineage 2F, which had an MIC of >32 μg/mL. It is 
possible that this mutation can greatly influence MIC, however it is unknown how much it 
affects cell growth.  
 A nonsense mutation in yahA was also present at a higher frequency in a separate lineage. 
yahA codes for a protein involved in signaling pathways. This falls after the DNA binding 
residues and the dimerization domains, and contains elements of the EAL superfamily, which is 
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shared among signaling proteins. The mutation cuts the EAL region short, and the protein might 
not successfully degrade cyclic diGMP, preventing signal transduction (Marchler-Bauer et al., 
2017). 
 Future experiments will clone the mutations from the evolved lineages into Hm21RS and 
MIC will be recorded to quantify the change in MIC. Additionally we hope to incorporate gyrA 
S83I, parC E91K, and pAv42 to observe the effect of these mutations in combination. Mutations 
will take priority in order of frequency. The first two mutations we will investigate are pncB 
T77P and phoE Δ367 cloned into Hm21RS. As part of this investigation, we will determine the 
contribution of each mutation to Cp resistance, along with experiments conducted in the current 
study.  
Additionally, Hm21RS gyrA parC pAv42 is being evolved in vivo in Hirudo verbana 
with blood meal feedings supplemented with Cp to observe CpR mutations from selective 
pressure. The conjugation method used to transfer pAv42 into the Hm21RS strains demonstrated 
a technique to transfer an unmodified vector into wild type strains for future studies. Further 
investigation would be necessary to improve the efficiency of the assay. 
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Conclusion 
 This study demonstrated the MIC of CpR strains and explored the interactions between 
the genetic factors that contributed to resistance. The MIC of Hm21RS rose from 0.01μg/mL to 3 
μg/mL, which was a statistically significant impact. While the presence of qnrS2 is shown to 
influence MIC, previously susceptible strains did not rise to levels considered resistant. This 
suggests that additional genetic factors are necessary for strains to reach resistant levels. The 
evolution of Hm21RS gyrA parC pAv42 revealed chromosomal mutations that might contribute 
to resistance factors. Of these, pncB T77P and phoE Δ367 occurred at the highest frequencies 
and are highest priority for future analysis. Additionally, a method for selecting plasmids with 
Cp resistance that do not carry selection markers was developed. This can prove useful for 
investigating the influence of the qnrs2 carrying IncU type plasmid found on other Aeromonas 
isolates.  
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Figure 1, Flowchart of Mutant Creation assay of Hm21RS parC gyrA 
pAv42. Cultures were refreshed every 24 hours with fresh media and in new 
wells in 96-well plate. After sequencing, downstream analysis using Breseq 
and Microsoft Excel filtered out any mutations found in LB control 
populations. 
Figures and Tables 
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Figure 2, Flowchart depicting the acquisition of mutations from Hm21 to Hm21RS and 
then transformation of pEL1 and pAv42 in Hm21RS. Green circles represent plasmids, 
orange represents mutations, and yellow represents strains. 
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Figure 3, Cp MIC of all isolates used in study. MIC was tested using E-Tests from bioMerieux, on 
Muller Hinton II media with 1.5% Bacto Agar, and incubated for 16-18 hours at 30°C. A Kruskal-
Wallis one-way ANOVA analysis found that the dataset had a P value of 0.003. A Kruskal-Wallis 
multiple comparisons analysis found a significant difference between Hm21RS and Hm21RS 
parC gyrA pAv42, and Hm21RS parC gyrA pAv42 vs. Hm21RS parC (P < 0.05)
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Figure 4, Growth curves for all strains in the present study, the Y axis is on a log scale. Hm21RS gyrA 
0.01 Cp is not displayed here(4A), because the wells were not inoculated. Each strain was grown in LB and 
LB with 0.01 μg/ml Cp. 4A are cultures in LB supplemented with Rif 20 Step 100 Cp 0.01. 4B are cultures 
in LB supplemented with Rif 20 Strep 100. The two abnormal curves are labeled; the upper curve is 
0.01Cp Hm21RS parC, while the lower curve is 0.01Cp Hm21RS.
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Table 2, List of mutations present in evolved populations of Hm21RS 
parC gyrA pAv42. Frequency was cut off at 10%. All populations were 
sequenced after the seventh day of selection. The number in each name 
corresponds to the concentration of Cp in μg/ml.
Logistic 
growth
Hm21RS 
pAv42 LB
Hm21RS 
pAv42 0.01 
Cp
Hm21RS 
gyrA 
pAv42 LB
Hm21RS 
gyrA 
pAv42 0.01 
Cp
Hm21RS 
parC 
pAv42 LB
Hm21RS 
parC 
pAv42 0.01 
Cp
Hm21RS 
parC gyrA 
pAv42 LB
Hm21RS 
parC gyrA 
pAv42 0.01 
Cp
Hm21RS 
LB
Hm21RS 
0.01 Cp
Hm21RS 
gyrA LB
Hm21RS 
gyrA 0.01 
Cp
Hm21RS 
parC LB
Hm21RS 
parC 0.01 
Cp
Hm21RS 
parC gyrA 
LB
Hm21RS 
parC gyrA 
0.01 Cp
Hm21RS 
parC gyrA 
pEL1 LB
Hm21RS 
parC gyrA 
pEL1 0.01 
Cp
Hm21RS 
pEL1 LB
Hm21RS 
pEL1 0.01 
Cp
Hm21RS 
gyrA pEL1 
LB
Hm21RS 
gyrA pEL1 
0.01 Cp
Best‐fit values
     YM 0.6804 0.6543 0.6561 0.6473 0.6733 0.6607 0.6479 0.6456 0.6423 0.4718 0.6707 0.6617 0.6822 0.8089 0.6662 0.6641 0.5928 0.5788 0.6097 0.6258 0.644 0.001998
     Y0 0.07839 0.07449 0.06539 0.06397 0.07951 0.07893 0.06172 0.06134 0.06458 0.002897 0.08058 0.0798 0.09035 0.04078 0.07603 0.07624 0.04616 0.04412 0.05456 0.05691 0.05893 0.0004953
     k 0.311 0.3256 0.3353 0.3344 0.3203 0.3225 0.3426 0.3384 0.3324 0.4044 0.3041 0.3091 0.2965 0.1563 0.3148 0.3125 0.3468 0.3567 0.3357 0.3276 0.3237 0.251
     Xint 3.215 3.071 2.983 2.991 3.122 3.101 2.919 2.955 3.009 2.473 3.288 3.235 3.373 6.399 3.176 3.2 2.884 2.803 2.979 3.052 3.09 3.985
Table 1, Nonlinear regression analysis of growth rates. YM is the maximum Y value, Y0 is the 
minimum Y value, k is the rate growth rate during the log phase, and Xint is X coordinate (time) 
of the first inflection point. 
Name Location Position (Bp) Mutation Frequency Annotation Gene Description Population Cp MIC (μg/ml)
2C Chromosome 4463153 A→C 100.0% T77P (ACC→CCC)  pncB → Nicotinate phosphoribosyltransferase 12
2E Chromosome 4463153 A→C 100.0% T77P (ACC→CCC)  pncB → Nicotinate phosphoribosyltransferase 6
2F Chromosome 1647203 Δ1 bp 53.2% coding (367/1038 nt) phoE_2 → Outer membrane pore protein E precursor >32
2C Chromosome 2721543 T→G 52.1% L203* (TTA→TGA)  yahA_2 → Cyclic di-GMP phosphodiesterase YahA 12
001D Chromosome 221270 +G 48.6% coding (450/723 nt) ompR_1 → Transcriptional regulatory protein OmpR 3
001B Chromosome 220894 T→C 41.8% L25P (CTC→CCC)  ompR_1 → Transcriptional regulatory protein OmpR 3
001D Chromosome 3417850 G→C 41.7% G280A (GGT→GCT)  PROKKA_03128 → Hom_end-associated Hint 3
001B Chromosome 1699992 Δ4 bp 34.9% coding (366-369/912 nt) hag_4 → Flagellin 3
001A Chromosome 221495 +GTCTGGG 34.4% coding (675/723 nt) ompR_1 → Transcriptional regulatory protein OmpR 4
2C Chromosome 3381134 Δ9 bp 22.9% coding (912-920/2229 nt) cheA_2 ← Chemotaxis protein CheA 12
001B Chromosome 2721348 G→A 17.6% W138* (TGG→TAG)  yahA_2 → Cyclic di-GMP phosphodiesterase YahA 3
001B Chromosome 3391607 A→T 15.3% L100Q (CTG→CAG)  PROKKA_03104 ← flagellar biosynthesis protein FliO 3
2C Chromosome 3250038 Δ11 bp 14.6% coding (333-343/576 nt) lon_3 → Lon protease 12
2D Chromosome 2745391 A→G 10.8% D504G (GAC→GGC)  arnA → Bifunctional polymyxin resistance protein ArnA 8
001A Chromosome 2722440 A→C 10.0% Q502P (CAG→CCG)  yahA_2 → Cyclic di-GMP phosphodiesterase YahA 4
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1,648,101 Δ21 bp
intergenic (+
227/+306)
phoE_2  → /
 ← tyrA
Outer 
membrane 
pore protein 
E 
precursor/T-
protein + + + + + + + + + + +
4,073,360 C→T
E91K (GAA
→AAA) parC  ←
DNA 
topoisomera
se 4 subunit 
A ‐ + ‐ + ‐ + + ‐ ‐ + +
4,327,562 T→C
K88R (AAA
→AGA) rpsL  ←
30S 
ribosomal 
protein S12 + + + + + + + + + + +
4,337,287 G→A
S531F (TC
C→TTC) rpoB  ←
DNA-directe
d RNA 
polymerase 
subunit beta + + + + + + + + + + +
2,072,261 T→G
G449G (GG
T→GGG) 
PROKKA_
01899  →
hypothetical 
protein ‐ ‐ = ‐ = ‐ ‐ ‐ = ‐ ‐
2,202,619 2 bp→TT
coding (248-249/2748 n
t) gyrA  →
DNA gyrase 
subunit A ‐ ‐ + + + ‐ + ‐ + ‐ +
Hm21_Contig2 1 Δ56,525 bp
PROKKA_
04331 –PR
OKKA_043
98 68 genes  + + + + + + + + + + +
4,728
+TGGCGT
C
intergenic (–
/–) – / – –/– + + + + N/A N/A N/A N/A
4,732 G→T
intergenic (–
/–) – / – –/– + + + + N/A N/A N/A N/A
4,743 Δ1 bp
intergenic (–
/–) – / – –/– + + + + N/A N/A N/A N/A
12,740 (C)6→5
coding (449
/513 nt)  →
Inner 
membrane 
protein 
forms 
channel for 
type IV 
secretion of 
T-DNA 
complex 
(VirB8) + + + + N/A N/A N/A N/A
19,603 +39 bp
coding (160
2/2910 nt)  →
hypothetical 
protein ‐ ‐ ‐ ‐ N/A N/A N/A N/A
8,799 T→C
F415L (TTC
→CTC)  →
ATPase 
provides 
energy for 
both 
assembly of 
type IV 
secretion 
complex 
and 
secretion of 
T-DNA 
complex 
(VirB4) ‐ ‐ + ‐ N/A N/A N/A N/A
33,332 C→T
intergenic (–
/–) – / – –/– ‐ ‐ ‐ ‐ N/A N/A N/A N/A
23,478 T→C
T101A (AC
C→GCC)  ←
IncQ 
plasmid 
conjugative 
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endonuclea
se TraR (pTi 
VirD2 
Homolog) ‐ ‐ ‐ ‐
586 (G)8→9
coding (806
/834 nt)  ←
modification 
methylase 
NspV N/A N/A N/A + + + N/A N/A N/A
8,143 (T)5→6
intergenic (–
/–) – / – –/– N/A N/A N/A + + + N/A N/A N/A
8,202 G→T
intergenic (–
/–) – / – –/– N/A N/A N/A + + + N/A N/A N/A
8,372 +G
intergenic (–
/–) – / – –/– N/A N/A N/A + + + N/A N/A N/A
8,700 +C
intergenic (–
/–) – / – –/– N/A N/A N/A + ‐ + N/A N/A N/A
Hm21_Contig1
contig_pAv42
contig_pEL1
Table 3,  Summary of Breseq mutant analysis of all final strains used in this study. +   
indicates presence of the mutation, while - indicates abscence, and = is for silent mutations. 
Hm21RS pEL1 needs to be sequenced. A visualization of this table can be seen in figure 2.
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evidence seq id position mutation annotation gene description LB1 LB2 LB3 001A7 001B7 001D7 001E7 001F7 2B7 2C7 2D7 2E7 2F7
MC
Hm21_co
ntig002 1 Δ56,525 bp PROKKA_04331–PROK68 genes 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA
Hm21_co
ntig001 147,001 T→C
F693F 
(TTT→TTC) lacZ → Beta galactosidase 6%
RA
Hm21_co
ntig001 200,879 T→C
N400D 
(AAC→GAC) pssA ←
CDP diacylglycerol
serine 
O
‑
phosphatidyltrans
ferase 6%
RA
Hm21_co
ntig001 220,894 T→C
L25P (CTC→C
CC) 
ompR_1  
→
Transcriptional 
regulatory protein 
OmpR 42%
RA
Hm21_co
ntig001 220,996 T→A
L59Q 
(CTG→CAG)
ompR_1 
→
Transcriptional 
regulatory protein 
OmpR 16%
JC
Hm21_co
ntig001 221,156 Δ120 bp
coding (336 4
55/723 nt)
ompR_1  
→
Transcriptional 
regulatory protein 
OmpR 28%
RA
Hm21_co
ntig001 221,188 G→T
R123L 
(CGC→CTC)
ompR_1 
→
Transcriptional 
regulatory protein 
OmpR 32%
RA
Hm21_co
ntig001 221,270 +G
coding (450/7
23 nt)
ompR_1  
→
Transcriptional 
regulatory protein 
OmpR 49%
JC
Hm21_co
ntig001 221,495 +GTCTGGG
coding (675/7
23 nt)
ompR_1  
→
Transcriptional 
regulatory protein 
OmpR 34%
RA
Hm21_co
ntig001 221,601 T→G
V21G 
(GTC→GGC)
envZ_1 
→
Osmolarity sensor 
protein EnvZ 45% 16%
RA
Hm21_co
ntig001 221,649 C→G
P37R (CCA→C
GA) 
envZ_1  
→
Osmolarity sensor 
protein EnvZ 67% 75%
RA
Hm21_co
ntig001 415,491 C→A
P142Q 
(CCG→CAG) murF →
UDP
‑
N
‑
acetylmuram
oyl
‑
tripeptide
‑‑
D
‑
ala
nyl
‑
D
‑
 alanine ligase
10%
RA
Hm21_co
ntig001 431,017 C→T
H31Y (CAT→T
AT) 
mutT  →
8 oxo dGTP 
diphosphatase 6%
RA
Hm21_co
ntig001 580,047 G→C
A40P 
(GCC→CCC)
PROKKA_
00549 → hypothetical protein 6%
RA
Hm21_co
ntig001 643,450 G→A
G86E (GGG→
GAG) 
nhaA  →
Na(+)/H(+) 
antiporter NhaA 6%
RA
Hm21_co
ntig001 776,347 G→T
G277V (GGC
→GTC) 
PROKKA_
00736  →
ABC 2 family 
transporter protein 6%
RA Hm21_co
ntig001
789,613 G→T
I35I (ATC→AT
A) 
PROKKA_
00748  ←
hypothetical protein 6%
RA Hm21_co
ntig001
807,438 T→A
V198V (GTA
→GTT) 
metI  ←
D methionine 
transport system 
permease protein 
MetI 6%
RA
Hm21_co
ntig001 812,624 G→A
G146D (GGC
→GAC) 
nnr  →
Bifunctional 
NAD(P)H
‑
hydrate 
repair enzyme Nnr 6%
RA
Hm21_co
ntig001 994,462 T→C
L258P (CTG→
CCG) 
hcpC  →
Putative 
beta
‑
lactamase 
HcpC precursor 6%
RA Hm21_co
ntig001
1,018,145 A→C
L26R (CTG→C
GG) 
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,147 +T coding (75/12
30 nt)
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
7%
RA Hm21_co
ntig001
1,018,149 C→G
A25P (GCC→
CCC) 
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
7%
RA Hm21_co
ntig001
1,018,151 T→A
Y24F (TAT→T
TT) 
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
7%
RA Hm21_co
ntig001
1,018,157 T→G
K22T (AAG→
ACG) ‡
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,158 T→C
K22E (AAG→
GAG) ‡
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
Table 4, Frequency analysis of all mutants detected from Breseq analysis of Hm21RS parC gyrA pAv42 evolved 
populations. Any lineage with 001 was grown in 0.01 Cp conditions with Rif20 Strep100. Any lineage with 2 was grown 
in 2.0 Cp conditions with Rif20 Strep100. Hm21_contig001 is the chromosome, and Hm21_contig_002 was a plasmid 
from Hm21 that was lost during the creation of Hm21RS, while contig_pAv42 represents pAv42. All frequencies are 
color coded from red to green, low to high. 
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RA Hm21_co
ntig001
1,018,159 G→C
A21A (GCC→
GCG) ‡
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,160 G→A
A21V (GCC→
GTC) ‡
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,161 C→A
A21S (GCC→T
CC) ‡
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,167 T→A
K19* (AAG→
TAG) 
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,169 Δ1 bp
coding (53/12
30 nt)
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,170 Δ1 bp
coding (52/12
30 nt)
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,171 A→G
G17G (GGT→
GGC) 
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA Hm21_co
ntig001
1,018,175 G→T
P16Q (CCG→
CAG) 
nqrB  ←
Na(+) translocating 
NADH
‑
quinone 
reductase subunit B
6%
RA
Hm21_co
ntig001 1,041,484 G→A
A214V (GCC
→GTC) 
ycdT_2  
←
putative diguanylate 
cyclase YcdT 5%
RA
Hm21_co
ntig001 1,068,603 G→A
Q265Q (CAG
→CAA) 
rseP  →
Regulator of sigma E 
protease RseP
6%
RA
Hm21_co
ntig001 1,095,047 C→T
R226H 
(CGT→CAT) gshB ←
Glutathione 
synthetase 6%
RA Hm21_co
ntig001
1,270,092 G→A
D34N (GAC→
AAC) 
ptsI_2  →
Phosphoenolpyruvat
e
‑
protein 
phosphotransferase
5%
RA Hm21_co
ntig001
1,278,218 G→A
T1030T (ACC
→ACT) 
mscK  ←
Mechanosensitive 
channel MscK 
precursor
6%
RA Hm21_co
ntig001
1,282,634 G→A
G83G (GGC→
GGT) 
pykF  ← Pyruvate kinase I 5%
RA Hm21_co
ntig001
1,365,580 A→G
F13F (TTT→T
TC) 
PROKKA_
01278  ←
hypothetical protein 6%
RA Hm21_co
ntig001
1,391,786 T→C
I617T (ATT→
ACT) 
PROKKA_
01300  →
Capsule 
polysaccharide 
biosynthesis protein
5%
RA Hm21_co
ntig001
1,471,544 G→T
T162N (ACC→
AAC) 
asnS  ← Asparagine tRNA 
ligase 5%
RA
Hm21_co
ntig001 1,486,039 G→C
G440G (GGG
→GGC) 
gltD_1  →
Glutamate synthase 
[NADPH] small chain
8%
RA
Hm21_co
ntig001 1,553,566 A→G
S373G (AGC
→GGC) 
entE  →
Enterobactin 
synthase 
component E 6%
RA
Hm21_co
ntig001 1,602,258 G→T
E379* 
(GAG→TAG) ntrC →
Nitrogen 
assimilation 
regulatory protein 8%
RA
Hm21_co
ntig001 1,605,204 C→T
H13Y (CAT→T
AT) 
PROKKA_
01484  →
Putative GTP 
cyclohydrolase 1 
type 2 6%
RA
Hm21_co
ntig001 1,647,203 Δ1 bp
coding (367/1
038 nt)
phoE_2  
→
Outer membrane 
pore protein E 
precursor 53%
JC
Hm21_co
ntig001 1,647,585 Δ3 bp
coding (749 7
51/1038 nt)
phoE_2  
→
Outer membrane 
pore protein E 
precursor 7%
MC JC
Hm21_co
ntig001 1,648,044 Δ21 bp
intergenic 
(+170/+363)
phoE_2 
→ / ← 
tyrA
Outer membrane 
pore protein E 
precursor/T
‑
protein
100% 100% 100%
RA Hm21_co
ntig001
1,664,532 A→T
Y119F (TAC→
TTC) 
pyrC  → Dihydroorotase 5%
RA Hm21_co
ntig001
1,675,927 C→A
H168N (CAT
→AAT) 
PROKKA_
01546  →
hypothetical protein 6%
JC Hm21_co
ntig001
1,699,992 Δ4 bp
coding (366 3
69/912 nt)
hag_4  → Flagellin 35%
34
RA
Hm21_co
ntig001 1,740,127 T→C
intergenic 
(+171/
‑
91)
yfcG_1 → 
/ → 
emrD
Disulfide
‑
bond 
oxidoreductase 
YfcG/Multidrug 
resistance protein D
6%
RA
Hm21_co
ntig001 1,776,349 A→G
*551*
(TAA→TGA) malF →
Maltose transport 
system permease 
protein MalF
5%
RA Hm21_co
ntig001
1,826,086 Δ1 bp
coding (507/1
458 nt)
rpfG_6  ←
Cyclic di
‑
GMP 
phosphodiesterase 
response regulator 
RpfG
6%
RA Hm21_co
ntig001
1,879,054 C→A
I103I (ATC→A
TA) 
cmk  → Cytidylate kinase 5%
RA Hm21_co
ntig001
1,912,930 A→G
Q33R (CAA→
CGA) 
PROKKA_
01760  →
Outer membrane 
protein Omp38 
precursor
10%
RA
Hm21_co
ntig001 1,935,697 A→G
H460R (CAC
→CGC) 
ycaO  →
Ribosomal protein 
S12 
methylthiotransfera
se accessory factor 
YcaO 7%
RA Hm21_co
ntig001
1,965,842 C→T
F196F (TTC→
TTT) 
sdhA  →
Succinate 
dehydrogenase 
flavoprotein subunit
7%
RA Hm21_co
ntig001
2,147,216 T→C
L415P (CTG→
CCG) 
guaD  → Guanine deaminase 6%
JC
Hm21_co
ntig001 2,181,798 Δ3 bp
coding (298 3
00/1185 nt)
PROKKA_
02004  ←
Acyltransferase 
family protein 8%
RA
Hm21_co
ntig001 2,202,619 2 bp→TT
coding 
(248 249/274
8 nt) gyrA →
DNA gyrase subunit 
A 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA Hm21_co
ntig001
2,251,493 A→G
K20E (AAA→
GAA) 
proQ  → ProP effector 6%
RA Hm21_co
ntig001
2,295,743 G→A
intergenic (
‑
1
68/
‑
92)
PROKKA_
02108  ← 
/ → PROK
KA_0210
9
Putative 
polyhydroxyalkanoic 
acid system protein 
(PHA_gran_rgn)/hyp
othetical protein
7%
RA
Hm21_co
ntig001 2,310,689 G→A
P56S (CCG→T
CG) 
holB  ←
DNA polymerase III 
subunit delta'
5%
RA Hm21_co
ntig001
2,344,033 C→G
R125P (CGC→
CCC) 
PROKKA_
02154  ←
Glutathione depend
ent 
formaldehyde
‑
activa
ting enzyme 6%
RA
Hm21_co
ntig001 2,358,235 A→G
T370A (ACC→
GCC) 
recQ_2  
→
ATP dependent DNA 
helicase RecQ
6%
RA
Hm21_co
ntig001 2,423,480 T→A
intergenic (
‑
4
27/
‑
349)
hydN  ← /
→ PROK
KA_0221
6
Electron transport 
protein 
HydN/hypothetical 
protein
6%
RA
Hm21_co
ntig001 2,430,273 C→G
A384G 
(GCC→GGC) hyfB →
Hydrogenase 4 
component B
8%
RA
Hm21_co
ntig001 2,466,417 G→A
V64V (GTG→
GTA) 
tuaH  →
Putative teichuronic 
acid biosynthesis 
glycosyltransferase 
TuaH
5%
RA Hm21_co
ntig001
2,555,252 C→T
intergenic (
‑
6
50/
‑
396)
PROKKA_
02325  ← 
/ → PROK
KA_0232
6
hypothetical 
protein/hypothetical 
protein
7%
RA Hm21_co
ntig001
2,588,503 T→C
F370S (TTT→
TCT) 
ptrA  → Protease 3 
precursor 5%
RA
Hm21_co
ntig001 2,604,817 A→T
D33V (GAT→
GTT) 
hrsA  →
Heat responsive 
suppressor HrsA
6%
RA
Hm21_co
ntig001 2,624,449 A→G
K421R 
(AAG→AGG)
PROKKA_
02379 →
Electron transfer 
flavoprotein
‑
ubiquin
one oxidoreductase
6%
RA Hm21_co
ntig001
2,637,184 T→C
M177V (ATG
→GTG) 
hemH  ← Ferrochelatase 6%
RA
Hm21_co
ntig001 2,652,416 G→T
V340V (GTG
→GTT) 
pleD_3  →
Response regulator 
PleD 5%
35
RA
Hm21_co
ntig001 2,672,540 C→T
E192K 
(GAG→AAG)
PROKKA_
02425 ←
Intracellular 
multiplication and 
human 
macrophage
‑
killing
5%
JC
Hm21_co
ntig001 2,720,967
+CCGCTGG
CATTGG
coding (32/15
78 nt)
yahA_2  
→
Cyclic di GMP 
phosphodiesterase 
YahA 9%
RA
Hm21_co
ntig001 2,721,348 G→A
W138* (TGG
→TAG) 
yahA_2  
→
Cyclic di GMP 
phosphodiesterase 
YahA 18%
RA
Hm21_co
ntig001 2,721,543 T→G
L203* (TTA→
TGA) 
yahA_2  
→
Cyclic di GMP 
phosphodiesterase 
YahA 52%
RA
Hm21_co
ntig001 2,722,193 G→A
G420S (GGC
→AGC) 
yahA_2  
→
Cyclic di GMP 
phosphodiesterase 
YahA 23%
JC
Hm21_co
ntig001 2,722,193 Δ3 bp
coding (1258
1260/1578 nt
)
yahA_2  
→
Cyclic di GMP 
phosphodiesterase 
YahA 12%
RA
Hm21_co
ntig001 2,722,199 G→A
G422S 
(GGT→AGT)
yahA_2 
→
Cyclic di GMP 
phosphodiesterase 
YahA 17%
RA
Hm21_co
ntig001 2,722,440 A→C
Q502P (CAG
→CCG) 
yahA_2  
→
Cyclic di GMP 
phosphodiesterase 
YahA 10%
RA
Hm21_co
ntig001 2,735,872 A→G
L90L 
(TTG→CTG)
PROKKA_
02474 ←
putative ISXO2 
transposase 8%
RA
Hm21_co
ntig001 2,735,884 G→T
P86T 
(CCG→ACG)
PROKKA_
02474 ←
putative ISXO2 
transposase 7%
RA
Hm21_co
ntig001 2,745,391 A→G
D504G (GAC
→GGC) 
arnA  →
Bifunctional 
polymyxin 
resistance protein 
ArnA 11%
RA Hm21_co
ntig001
2,772,161 T→C
intergenic (
‑
1
4/
‑
248)
PROKKA_
02518  ← 
/ → recQ
_3
tellurite resistance 
protein 
TehB/ATP
‑
depende
nt DNA helicase 
RecQ
7%
RA Hm21_co
ntig001
2,772,290 A→G
intergenic (
‑
1
43/
‑
119)
PROKKA_
02518  ← 
/ → recQ
_3
tellurite resistance 
protein 
TehB/ATP
‑
depende
nt DNA helicase 
RecQ
5%
RA
Hm21_co
ntig001 2,782,628 A→G
T262A (ACC→
GCC) 
efeU  →
Ferrous iron 
permease EfeU 5%
RA
Hm21_co
ntig001 2,794,470 C→T
intergenic (+2
72/
‑
288)
PROKKA_
02532  → 
/ → PROK
KA_0253
3
Hydroxyneurospore
ne synthase 
(CrtC)/hypothetical 
protein
8%
RA Hm21_co
ntig001
2,796,711 A→G
N652D (AAT
→GAT) 
PROKKA_
02533  →
hypothetical protein 5%
RA
Hm21_co
ntig001 2,843,230 T→C
N232D (AAC
→GAC) 
rlmN  ←
Dual specificity RNA 
methyltransferase 
RlmN 7%
RA
Hm21_co
ntig001 2,959,642 C→T
R99H (CGT→
CAT) 
msbA_2  
←
Lipid A export 
ATP
‑
binding/permea
se protein MsbA
10%
RA Hm21_co
ntig001
3,064,353 A→G
N149D (AAC
→GAC) 
PROKKA_
02799  →
hypothetical protein 6%
RA
Hm21_co
ntig001 3,100,596 G→A
A17T 
(GCA→ACA)
malE_2 
→
Maltose binding 
periplasmic protein 
precursor
5%
RA
Hm21_co
ntig001 3,130,815 T→C
T113A (ACC→
GCC) 
viuB  ←
Vibriobactin 
utilization protein 
ViuB 6%
RA Hm21_co
ntig001
3,141,874 T→C
I286T (ATC→
ACC) 
tus  →
DNA replication 
terminus 
site
‑
binding protein
6%
RA Hm21_co
ntig001
3,188,823 T→C
intergenic (
‑
2
79/
‑
95)
ribB  ← / 
→ purU
3,4
‑
dihydroxy
‑
2
‑
but
anone 4
‑
phosphate 
synthase/Formyltetr
ahydrofolate 
deformylase
6%
JC Hm21_co
ntig001
3,250,038 Δ11 bp
coding (333 3
43/576 nt)
lon_3  → Lon protease 15%
36
RA
Hm21_co
ntig001 3,303,603 T→C
V3V (GTA→G
TG) 
exsC  ←
Exoenzyme S 
synthesis protein C 
precursor 6%
RA
Hm21_co
ntig001 3,379,152 A→C
L214R 
(CTG→CGG) cheB1 ←
Chemotaxis 
response regulator 
protein
‑
glutamate 
methylesterase of 
group 1 operon
8%
RA
Hm21_co
ntig001 3,380,666 T→G
D463A 
(GAT→GCT)
cheA_2 
←
Chemotaxis protein 
CheA 19%
JC Hm21_co
ntig001
3,381,134 Δ9 bp
coding (912 9
20/2229 nt)
cheA_2  
←
Chemotaxis protein 
CheA 23%
RA
Hm21_co
ntig001 3,391,607 A→T
L100Q (CTG→
CAG) 
PROKKA_
03104  ←
flagellar 
biosynthesis protein 
FliO 15%
RA Hm21_co
ntig001
3,417,850 G→C
G280A (GGT
→GCT) 
PROKKA_
03128  →
Hom_end associate
d Hint 42%
RA
Hm21_co
ntig001 3,484,613 C→A
L341L (CTC→
CTA) 
patB_2  
→
Cystathionine 
beta
‑
lyase PatB 5%
RA
Hm21_co
ntig001 3,530,359 A→T
E88D 
(GAA→GAT)
yqaB_1 
→
Fructose 1 phosphat
e phosphatase YqaB
6%
RA
Hm21_co
ntig001 3,566,160 C→A
Q360K (CAG
→AAG) 
pctA_2  →
Methyl accepting 
chemotaxis protein 
PctA 5%
RA
Hm21_co
ntig001 3,690,651 G→A
A34T 
(GCC→ACC)
PROKKA_
03383 → hypothetical protein 6%
RA
Hm21_co
ntig001 3,805,937 G→A
G277S 
(GGT→AGT)
ctpH_2 
→
Methyl accepting 
chemotaxis protein 
CtpH 15%
RA
Hm21_co
ntig001 3,815,091 C→T
R51H 
(CGC→CAC) basR ←
Transcriptional 
regulatory protein 
BasR 6%
RA Hm21_co
ntig001
3,851,358 C→T
A74T (GCC→
ACC) 
ispD  ←
2 C methyl D erythr
itol 4
‑
phosphate 
cytidylyltransferase
5%
RA
Hm21_co
ntig001 3,880,698 G→A
A105T (GCT→
ACT) 
dehH1  →
Haloacetate 
dehalogenase H
‑
1 5%
RA Hm21_co
ntig001
3,925,976 T→C
D385D (GAT
→GAC) 
rpfG_10  
→
Cyclic di
‑
GMP 
phosphodiesterase 
response regulator 
RpfG
6%
JC Hm21_co
ntig001
3,962,579 Δ5 bp
coding (381 3
85/624 nt)
PROKKA_
03619  ←
hypothetical protein 8%
RA
Hm21_co
ntig001 4,000,838 G→T
C72* (TGC→T
GA) 
rlmCD  ←
23S rRNA 
(uracil
‑
C(5))
‑
methylt
ransferase RlmCD 6%
RA
Hm21_co
ntig001 4,073,360 C→T
E91K 
(GAA→AAA) parC ←
DNA topoisomerase 
4 subunit A
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA Hm21_co
ntig001
4,200,255 G→A
intergenic (
‑
3
44/
‑
162)
amtB  ← /
→ ydaM
_6
Ammonia channel 
precursor/putative 
diguanylate cyclase 
YdaM
8%
RA
Hm21_co
ntig001 4,217,352 G→A
Y85Y (TAC→T
AT) 
thiC  ←
Phosphomethylpyri
midine synthase 7%
RA
Hm21_co
ntig001 4,327,562 T→C
K88R 
(AAA→AGA) rpsL ←
30S ribosomal 
protein S12 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA
Hm21_co
ntig001 4,337,287 G→A
S531F 
(TCC→TTC) rpoB ←
DNA directed RNA 
polymerase subunit 
beta 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA
Hm21_co
ntig001 4,463,153 A→C
T77P (ACC→C
CC) 
pncB  →
Nicotinate 
phosphoribosyltrans
ferase 100% 100%
RA Hm21_co
ntig001
4,472,901 A→C
intergenic (
‑
5
0/+26)
pyrE  ← / 
← rph
Orotate 
phosphoribosyltrans
ferase/Ribonuclease 
PH 6%
RA
Hm21_co
ntig001 4,481,839 T→C
K364K 
(AAA→AAG)
hsdS_2 
←
Type
‑
1 restriction 
enzyme EcoKI 
specificity protein
7%
RA
Hm21_co
ntig001 4,496,583 C→T
A75T 
(GCA→ACA)
PROKKA_
04130 ←
flagellar 
biosynthesis protein 
FliR 5%
37
RA
Hm21_co
ntig001 4,592,511 G→A
H37H 
(CAC→CAT) hemG ←
Protoporphyrinogen 
IX dehydrogenase 
[menaquinone]
5%
RA
Hm21_co
ntig001 4,708,172 C→A
E219* (GAG
→TAG) 
tcyC  ←
L cystine import 
ATP
‑
binding protein 
TcyC 5%
RA contig_pA
v42
1,031 A→C
intergenic (
‑
5
74/+1406)
Replicati
on 
protein 
← / ← hy
pothetica
l protein
Replication 
protein/hypothetical 
protein
7%
JC contig_pA
v42
1,031
6 bp→104 b
p
intergenic (
‑
5
74/+1401)
Replicati
on 
protein 
← / ← hy
pothetica
l protein
Replication 
protein/hypothetical 
protein
24% 27%
RA
contig_pA
v42 1,032 A→G
intergenic 
(
‑
575/+1405)
Replicati
on 
protein 
← / ← 
hypotheti
cal 
protein
Replication 
protein/hypothetical 
protein
5% 6% 5% 8%
RA
contig_pA
v42 1,036 T→C
intergenic 
(
‑
579/+1401)
Replicati
on 
protein 
← / ← 
hypotheti
cal 
protein
Replication 
protein/hypothetical 
protein
5% 5% 6% 5% 9%
JC contig_pA
v42
1,075 +98 bp
intergenic (
‑
6
18/+1362)
Replicati
on 
protein 
← / ← hy
pothetica
l protein
Replication 
protein/hypothetical 
protein
72%
RA
contig_pA
v42 1,076 C→A
intergenic 
(
‑
619/+1361)
Replicati
on 
protein 
← / ← 
hypotheti
cal 
protein
Replication 
protein/hypothetical 
protein
54% 62% 27% 56% 51% 52%
JC
contig_pA
v42 1,076
38 bp→137 
bp
intergenic 
(
‑
619/+1324)
Replicati
on 
protein 
← / ← 
hypotheti
cal 
protein
Replication 
protein/hypothetical 
protein
26% 34% 28% 25% 17% 25% 35%
RA
contig_pA
v42 1,091 C→T
intergenic 
(
‑
634/+1346)
Replicati
on 
protein 
← / ← 
hypotheti
cal 
protein
Replication 
protein/hypothetical 
protein
24% 33% 32% 26% 24% 26%
JC contig_pA
v42
1,093 +118 bp
intergenic (
‑
6
36/+1344)
Replicati
on 
protein 
← / ← hy
pothetica
l protein
Replication 
protein/hypothetical 
protein
39% 48%
JC
contig_pA
v42 1,113 +98 bp
intergenic 
(
‑
656/+1324)
Replicati
on 
protein 
← / ← 
hypotheti
cal 
protein
Replication 
protein/hypothetical 
protein
73% 60% 57% 56% 59% 55% 59% 59% 62% 66% 63% 60% 55%
JC
contig_pA
v42 4,727 +CTGGCGT
intergenic 
(
‑
1885/
‑
148)
putative 
integral 
membra
ne 
protein 
← / → 
DNA 
topoisom
erase I
putative integral 
membrane 
protein/DNA 
topoisomerase I (EC 
5.99.1.2)
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA
contig_pA
v42 4,732 G→T
intergenic 
(
‑
1890/
‑
143)
putative 
integral 
membra
ne 
protein 
← / → 
DNA 
topoisom
erase I
putative integral 
membrane 
protein/DNA 
topoisomerase I (EC 
5.99.1.2)
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
38
RA
contig_pA
v42 4,742 Δ1 bp
intergenic 
(
‑
1900/
‑
133)
putative 
integral 
membra
ne 
protein 
← / → 
DNA 
topoisom
erase I
putative integral 
membrane 
protein/DNA 
topoisomerase I (EC 
5.99.1.2)
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA
contig_pA
v42 12,735 Δ1 bp
coding 
(444/513 nt)
Inner 
membra
ne 
protein 
forms 
channel 
for type I 
→
Inner membrane 
protein forms 
channel for type IV 
secretion of T
‑
DNA 
complex (VirB8)
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
RA
contig_pA
v42 19,564 C→T
A521A 
(GCC→GCT)
hypotheti
cal 
protein 
→
hypothetical protein
16% 48% 46% 44% 22% 48% 47% 22%
RA
contig_pA
v42 19,579 A→G
Q526Q 
(CAA→CAG)
hypotheti
cal 
protein 
→
hypothetical protein
34% 49% 46% 46% 41% 52% 49% 38%
JC
contig_pA
v42 19,603 +156 bp
coding 
(1602/2910 
nt)
hypotheti
cal 
protein 
→
hypothetical protein
65% 84% 78% 81% 79%
RA
contig_pA
v42 19,604 A→G
T535A 
(ACC→GCC)
hypotheti
cal 
protein 
→
hypothetical protein
46% 48% 52% 49% 42% 45% 47% 40%
RA
contig_pA
v42 19,611 G→A
G537D 
(GGC→GAC)
hypotheti
cal 
protein 
→
hypothetical protein
29% 46% 49% 48% 31% 44% 44% 30%
JC
contig_pA
v42
19,620 +156 bp
coding (1619/
2910 nt)
hypotheti
cal 
protein 
→
hypothetical protein
58% 56% 54% 54% 53%
RA contig_pA
v42
29,614 C→T
G300D (GGC
→GAC) 
KfrA  ← KfrA 8% 7%
RA
contig_pA
v42 33,332 C→T
intergenic 
(
‑
248/+171)
hypotheti
cal 
protein 
← / ← 
Replicati
on 
protein
hypothetical 
protein/Replication 
protein
77% 39% 77% 83% 81% 83% 80% 77% 84% 87% 83% 83% 75%
RA
contig_pA
v42 33,343 A→G
intergenic 
(
‑
259/+160)
hypotheti
cal 
protein 
← / ← 
Replicati
on 
protein
hypothetical 
protein/Replication 
protein
20% 54% 19% 13% 15% 13% 16% 20% 11% 11% 16% 14% 19%
RA
contig_pA
v42 33,361 C→T
intergenic 
(
‑
277/+142)
hypotheti
cal 
protein 
← / ← 
Replicati
on 
protein
hypothetical 
protein/Replication 
protein
15% 25% 12% 9% 8% 6% 12% 14% 7% 8% 13% 10% 8%
RA
contig_pA
v42 33,362 A→G
intergenic 
(
‑
278/+141)
hypotheti
cal 
protein 
← / ← 
Replicati
on 
protein
hypothetical 
protein/Replication 
protein
17% 25% 12% 9% 9% 9% 14% 13% 10% 8% 16% 11% 8%
39
Target Name Sequence (5’ to 3’) Melting Tm (°C) 
pAv42 IncU_Test_2_F TGAGCAAATCCGAAGCCAG 63 
pAv42 IncU_Test_2_R GCAAAACCAACGACATTCCC 63 
pEl1 & qnrS2 IncU_Test_3_F GATGTCGCAGACCTTCGC 64 
pEl1 & qnrS2 IncU_Test_3_R AAACAACAATACCCAACGCTTC 63 
Table 5, List of primers used for confirmatory assays for conjugation of pAv42 and pEL1. Each primer has a Tm of 
about 63°C and was amplified using Gotaq Green Master Mix. The expected length of each fragment was about 500 
bp. Primers for IncU_Test_2 were specific to pAv42, while IncU_Test_3 primers targeted qnrS2 and were also used 
to identify pEL1 after transformation. Input DNA was usually sourced from cells suspended in molecular grade 
water (MGH2O) and boilated at 90°C.  
Target Direction Sequence (5’ to 3’) 
p1471 Forward CCCAAGAGGAACAAATCGCTC 
p1471 Reverse GGGGCAACCATAAAAACAGC 
pKAS46 Forward GCTGTTTTTATGGTTGCCCCgagcgtgacaatcacgaaac 
pKAS46 Reverse AGCGATTTGTTCCTCTTGGGggtgttgctgactcataccag 
Table 6, List of primers used for preparing fragments for Gibson assembly of pEL1. PCR reaction was done using 
Phusion Master Mix (New England Biolabs, Ipswitch, Massachusetts). Lowercase nucleotides indicate tails to make 
overhangs that causes the pKAS64 fragment to anneal to p1471. Gibson assembly was completed by using the 
Gibson Assembly Master Mix (New England Biolabs).  
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